(Q53411921)

14 May 2018

review article

1 reference

title

[Evaluation of early response to antiangiogenic treatment with dynamic contrast enhanced ultrasound] (English)

1 reference

14 May 2018

main subject

angiogenesis inhibitor

1 reference

Lassau N

1

1 reference

14 May 2018

Brule A

2

1 reference

14 May 2018

Chami L

3

1 reference

14 May 2018

Benatsou B

4

1 reference

14 May 2018

Péronneau P

5

1 reference

14 May 2018

Roche A

6

1 reference

14 May 2018

publication date

1 May 2008

1 reference

14 May 2018

published in

Journal de radiologie

1 reference

14 May 2018

volume

89

1 reference

14 May 2018

issue

5 Pt 1

1 reference

14 May 2018

page(s)

549-555

1 reference

14 May 2018

Molecular imaging of antiangiogenic agents.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Angiogenesis imaging--ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

New hemodynamic approach to angiogenesis: color and pulsed Doppler ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Phase II trial of thalidomide in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

[Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents]

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

We should desist using RECIST, at least in GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Quantification of flow rates using harmonic grey-scale imaging and an ultrasound contrast agent: an in vitro and in vivo study

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Contrast-specific ultrasonic flow measurements based on both input and output time intensities

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

[Recent advances in contrast-enhanced ultrasound for oncology applications]

1 reference

https://api.crossref.org/works/10.1016%2FS0221-0363%2808%2971480-X

7 January 2021

10.1016/S0221-0363(08)71480-X

Identifiers

DOI

1 reference

14 May 2018

1 reference

14 May 2018